# Medherant

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medherant

- Industry: Pharmaceuticals
- Headquarters: Coventry, UK
- Website: www.medherant.co.uk
- Total disclosed funding: $6.2M
- Latest round: Series A (May 20, 2019)
- Investors on record: 1

## About

Medherant Limited is a UK-based company specializing in innovative transdermal drug delivery systems, utilizing its proprietary TEPI Patch® technology to enhance medication administration.Founded in 2015 in Coventry, UK, Medherant Limited focuses on developing transdermal drug delivery solutions. The company has successfully completed 5 funding deals, with the latest funding round occurring in March 2023, where it raised GBP 3 million from Mercia Asset Management. The founder, Nigel Davis, has a history of involvement in the pharmaceutical sector.Medherant specializes in the creation of innovative transdermal drug delivery systems, chiefly through its proprietary TEPI Patch® technology. This advanced platform provides an effective and comfortable means of administering medications for various health concerns, particularly women’s health, pain management, and central nervous system (CNS) diseases. The TEPI Patch® allows drugs to permeate the skin, offering a non-invasive treatment option that enhances convenience and compliance. The company targets healthcare providers, pharmaceutical partners, and patients as its core clientele, addressing critical needs within these segments and marketing its products across Europe and North America.Medherant generates revenue through strategic partnerships and collaborations within the pharmaceutical sector, leveraging its TEPI Patch® technology for various applications. The company operates predominantly on a B2B model, focusing on licensing agreements and contract manufacturing arrangements with healthcare companies. Revenue is derived from upfront fees associated with licensing the TEPI Patch® technology, milestone payments linked to product development, and ongoing royalties based on sales of products incorporating Medherant’s technology. This structured revenue generation approach supports the company’s financial sustainability.In April 2023, Medherant Limited raised GBP 3 million in venture funding to accelerate its growth and research & development initiatives. The company plans to expand its product lineup of transdermal solutions, although specific new products and release dates have not been disclosed. Additionally, Medherant aims to penetrate new geographical markets, particularly targeting Europe and North America for further expansion. The recent funding will bolster these efforts, enabling the company to enhance its research capabilities and broaden its market reach.

## Funding rounds

- Series A, May 20, 2019, $6.2M — Mercia Asset Management

## Investors

- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Series A